What is Leerink Partnrs’ Estimate for ABVX FY2029 Earnings?

ABIVAX Société Anonyme (NASDAQ:ABVX) – Equities research analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for ABIVAX Société Anonyme in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will earn ($0.17) per share for the year. The consensus estimate for ABIVAX Société Anonyme’s current full-year earnings is ($2.92) per share.

Several other research analysts also recently weighed in on the company. JMP Securities reiterated a “market outperform” rating and set a $33.00 price target on shares of ABIVAX Société Anonyme in a research note on Friday, January 10th. Citizens Jmp upgraded shares of ABIVAX Société Anonyme to a “strong-buy” rating in a research report on Wednesday, December 4th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, ABIVAX Société Anonyme presently has an average rating of “Buy” and a consensus price target of $38.67.

ABIVAX Société Anonyme Price Performance

NASDAQ:ABVX opened at $6.03 on Thursday. The business has a fifty day simple moving average of $7.08 and a two-hundred day simple moving average of $9.52. ABIVAX Société Anonyme has a 1 year low of $5.49 and a 1 year high of $17.02.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC purchased a new stake in shares of ABIVAX Société Anonyme in the fourth quarter worth about $29,000. R Squared Ltd bought a new stake in ABIVAX Société Anonyme during the 4th quarter worth approximately $36,000. BNP Paribas Financial Markets lifted its stake in ABIVAX Société Anonyme by 82.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after purchasing an additional 5,900 shares in the last quarter. Walleye Capital LLC grew its position in shares of ABIVAX Société Anonyme by 45.8% during the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock valued at $2,965,000 after purchasing an additional 80,807 shares in the last quarter. Finally, abrdn plc grew its position in shares of ABIVAX Société Anonyme by 167.7% during the 3rd quarter. abrdn plc now owns 316,431 shares of the company’s stock valued at $3,645,000 after purchasing an additional 198,225 shares in the last quarter. Institutional investors own 47.91% of the company’s stock.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.